Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with retinoic acid in malignant melanoma.

被引：0
|
作者：
Kato, Y
Wang, XF
Qian, DZ
Wei, YF
Zhang, L
Atadja, P
Pili, R
机构：
[1] Johns Hopkins Univ, Baltimore, MD 21218 USA
[2] Novartis Pharma AG, Basel, Switzerland
来源：
CLINICAL CANCER RESEARCH | 2003年 / 9卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6253S / 6253S
页数：1
相关论文
共 50 条
  • [41] The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584
    Qian, DZ
    Wang, XF
    Kachhap, SK
    Kato, Y
    Wei, YF
    Zhang, L
    Atadja, P
    Pili, R
    CANCER RESEARCH, 2004, 64 (18) : 6626 - 6634
  • [42] A combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 is highly active against human AML cells with constitutively active mutant FLT-3 tyrosine kinase.
    Bhalla, KN
    Bali, P
    George, P
    Tao, J
    Guo, F
    Sigua, C
    Vishvanath, A
    Moscinski, L
    Cohen, P
    Atadja, P
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6233S - 6234S
  • [43] Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo
    E Weisberg
    L Catley
    J Kujawa
    P Atadja
    S Remiszewski
    P Fuerst
    C Cavazza
    K Anderson
    J D Griffin
    Leukemia, 2004, 18 : 1951 - 1963
  • [44] Antitumor effect of the histone deacetylase inhibitor MS-275 in combination with retinoic acid Am80 in human cutaneous T-cell lymphoma
    Kato, Yukihiko
    Egusa, Chizu
    Maeda, Tatsuo
    Tsuboi, Ryoji
    CANCER RESEARCH, 2012, 72
  • [45] Combined treatment with histone deacetylase inhibitor LAQ824 and Apo-2L/TRAIL: Mechanistic basis of superior activity against human acute leukemia and CML-BC cells.
    Li, YQ
    Guo, F
    Sigua, C
    Tao, JG
    Bali, P
    Vishvanath, A
    Gutti, R
    George, P
    Moscinski, L
    Atadja, P
    Bhalla, KN
    BLOOD, 2003, 102 (11) : 595A - 595A
  • [46] Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo
    Weisberg, E
    Catley, L
    Kujawa, J
    Atadja, P
    Remiszewski, S
    Fuerst, P
    Cavazza, C
    Anderson, K
    Griffin, JD
    LEUKEMIA, 2004, 18 (12) : 1951 - 1963
  • [47] Effects of the histone deacetylase inhibitor (HDACI) LAQ824 on histone acetylation, Hsp70 and c-Raf in peripheral blood lymphocytes from patients with advanced solid tumours enrolled in a phase I clinical trial
    Kristeleit, RS
    Tandy, D
    Atadja, P
    Patnaik, A
    Scott, J
    De Bono, JS
    Judson, I
    Kaye, SB
    Workman, P
    Aherne, W
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 200S - 200S
  • [48] Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions
    Rosato, Roberto R.
    Almenara, Jorge A.
    Maggio, Sonia C.
    Coe, Stefanie
    Atadja, Peter
    Dent, Paul
    Grant, Steven
    MOLECULAR CANCER THERAPEUTICS, 2008, 7 (10) : 3285 - 3297
  • [49] The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy
    Ellis, Leigh
    Bots, Michael
    Lindemann, Ralph K.
    Bolden, Jessica E.
    Newbold, Andrea
    Cluse, Leonie A.
    Scott, Clare L.
    Strasser, Andreas
    Atadja, Peter
    Lowe, Scott W.
    Johnstone, Ricky W.
    BLOOD, 2009, 114 (02) : 380 - 393
  • [50] Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation
    Cuneo, Kyle C.
    Fu, Allie
    Osusky, Katherine
    Huamani, Jessica
    Hallahan, Dennis E.
    Geng, Ling
    ANTI-CANCER DRUGS, 2007, 18 (07) : 793 - 800
12345